<DOC>
	<DOCNO>NCT01269294</DOCNO>
	<brief_summary>The purpose study evaluate effect TMC435 result electrocardiograms ( ECGs ) healthy volunteer . An electrocardiogram electric record heart . TMC435 investigate treatment chronic hepatitis C virus infection .</brief_summary>
	<brief_title>TMC435-TiDP16-C117 : The Effect TMC435 Results Electrocardiograms ( Electric Recording Heart ) Healthy Volunteers</brief_title>
	<detailed_description>This double-blind , double-dummy , randomize , 4-period cross-over , placebo- positive-controlled , Phase I study . This mean neither study doctor participant know treatment session receive active medication match placebo . Every participant receive 4 treatment session ( Treatments A , B , C D ) different order . The order receive treatment session determine chance , like toss coin . The purpose study evaluate effect TMC435 result electrocardiograms ( electric record heart ) . Two dose regimen TMC435 test , ie , 150 mg daily ( dose give patient ) 350 mg daily ( dose high one give patient ) , administer 7 day . A single dose 400 mg moxifloxacin use positive control assess trial sensitivity . The trial population consist 60 healthy volunteer approximately 18 female . In treatment , dummy capsule add order number capsule treatment . Treatment A consist 150 mg TMC435 daily 7 day ( 2 capsule TMC435 2 capsule placebo day 1-7 , 1 placebo tablet moxifloxacin Day 7 ) . Treatment B consist 350 mg TMC435 daily 7 day ( 4 capsule TMC435 Days 1-7 , 1 placebo tablet moxifloxacin Day 7 ) . Treatment C consist 400 mg moxifloxacin Day 7 ( 4 capsule placebo TMC435 Days 1-7 , 1 moxifloxacin tablet Day 7 ) . In Treatment D placebo give ( 4 capsule placebo TMC435 Days 1-7 , 1 placebo tablet moxifloxacin Day 7 ) . There washout period least 10 day subsequent treatment . A pharmacogenomic blood sample ( DNA sample , blood sample genetic information analyze ) collect volunteer analyze upon observation irregular electrocardiogram study . The purpose see irregularity electrocardiogram link genetic variant . DNA sample may also analyze additional gene relate pharmacokinetics ( body drug ) , pharmacodynamics ( drug body ) safety tolerability TMC435 study , necessary . Two oral dos TMC435 ( 150 350 mg ) placebo give daily 7 consecutive day . A single dose moxifloxacin 400 mg administer orally Day 7 one treatment session .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Nonsmokers least six month Have body mass index 18.0 30.0 kg per square meter Be healthy basis physical examination , medical history , vital sign , clinical laboratory test perform screen . Use disallow therapy , include overthecounter product dietary supplement Any skin condition likely interfere ECG electrode placement adhesion History evidence current use alcohol recreational narcotic drug use Clinically relevant abnormality ECG screen history clinically relevant heart rhythm disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435-TiDP16-C117</keyword>
	<keyword>TMC435-C117</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>ECG</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
</DOC>